| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anesthetic Procedure Patients were premedicated orally with midazolam 7.5 mg, 20–30 min before anesthesia. They were monitored with electrocardiogram, noninvasive arterial blood pressure (one measurement every 5 min), and oxygen saturation using pulse oximetry. General anesthesia was induced with IV fentanyl 0.15–0.2 mg; thiopental 5–7 mg/kg or propofol 2–2.5 mg/kg or etomidate 0.2–0.3 mg/kg; vecuronium 0.1 mg/kg or atracurium 0.5 mg/kg. After tracheal intubation, a mixture of oxygen (30% inspired concentration) with nitrous oxide was administered, supplemented by either isoflurane (0.3–0.5 vol% end-tidal concentration) or propofol (2–4 µg/mL target-controlled infusion). If there were signs of inadequate analgesia, IV boluses of 0.05–0.2 mg fentanyl and 1.0–2.0 mg vecuronium or atracurium 10–20 mg were administered at the discretion of the attending anesthesiologist. At the end of surgery, residual neuromuscular blockade was reversed with 2.5 mg neostigmine and 0.5 mg glycopyrrolate. Regional anesthesia was performed as a single-shot injection of a maximum 50 mL of mepivacaine 1% with sodium bicarbonate or ropivacaine 0.75% for peripheral nerve blockade and 12.5–17.5 mg bupivacaine 0.5% for spinal anesthesia. For general anesthesia, the trachea was extubated as soon as patients opened their eyes to verbal command and had sufficient respiration. If extubation was not performed within 1 h after the end of the operation, the patient was excluded from the study. For regional anesthesia, patients who did not require the first PCA dose within the first 2 h after the end of the operation were excluded from the study.
Rationale for Choosing the Studied Dose of Ketamine Drug combinations are generally investigated by comparing two or more groups, each receiving a different combination. However, this approach is challenged by a serious problem: the number of possible combinations. If we combine 2 different drugs and analyze 2 doses for each drug, there are 22 = 4 different combinations. However, if the therapeutic range of the drugs under investigation is wide, we might want to analyze more combinations, e.g., 5. In this case, we had to analyze 52 = 25 different combinations. If we want to add an additional variable, e.g., another drug or the time interval between the doses, the number of possible combinations increases to 53 = 125. Therefore, only a small portion of all possible combinations is investigated in a randomized controlled trial. Such a trial allows conclusions pertaining to the combinations analyzed, and the optimal combination may not be tested.
Direct Search Optimization Method We implemented the method developed by Berenbaum14 to optimize a postoperative epidural regimen15,16 and IV PCA with morphine and ketamine.17 One hundred and two patients undergoing lumbar spine or hip surgery participated in our optimization study.12 Initially, eight combinations of morphine, ketamine, and lockout interval (i.e., minimal allowed time between two consecutive PCA boluses) were empirically chosen and investigated. To determine subsequent combinations, an optimization model was applied until three consecutive steps showed no decrease in pain score. We analyzed 12 combinations with an allowed morphine and ketamine range in PCA solution of 0–2 mg/mL and a lockout interval range of 5–12 min. During the optimization procedure, a reduction in mean pain scores with a low incidence of side effects was observed. The procedure converged to a morphine: ketamine ratio of 1:1 and a lockout interval of 8 min. This combination was used in the present study.
Postoperative Management Patients with ASA physical status more than two were kept in the recovery room until the morning after the operation. During this time, oxygen saturation using pulse oximetry was continuously measured. Patients were moved to the ward when cardiocirculatory and respiratory function were stable. Oxygen 2–4 L/min via nasal probe was administered to maintain an oxygen saturation of more than 93%. Patients were randomly allocated to receive PCA consisting of either morphine 1.5 mg (Group M) or morphine with ketamine 1.5 mg of each (Group MK). In both groups, the PCA pump was programmed to deliver a maximum of 6 boluses per hour, with a lockout time (i.e., the minimum time allowed between two boluses) of 8 min.
The verbal rating score was recorded every 2 h during the first 6 h and every 4 h thereafter by asking patients to rate pain at rest and during mobilization as follows: 0 = no pain, 1 = mild, 2 = moderate, 3 = strong, and 4 = severe pain. Mobilization was defined as passively turning patients on their sides for nursing procedures. Adequate analgesia was defined as a score of 0 at rest and Sedation was recorded according to the following score: 0 = alert; 1 = drowsy; 2 = asleep, easily arousable to verbal commands, does not fall asleep during or immediately after conversation; 3 = asleep, opens the eyes to verbal command, falls asleep during or immediately after conversation; 4 = does not open eyes to verbal command. A maximum score of 3 during the first 12 postoperative hours or 2 during the subsequent observation period was acceptable. In the presence of higher scores, the PCA bolus was reduced by 0.5 mg every hour until the patient recovered from sedation to acceptable levels. If a respiratory rate of <8 per minute for a period longer than 10 min was observed, the PCA pump was stopped until a respiratory rate of 8 per minute was reached. The PCA regimen was then restarted using a PCA bolus of 0.5 mg less than the previous one. In the presence of nausea, with or without vomiting, ondansetron 4 mg IV was given and repeated if nausea did not disappear. If nausea was not relieved after the administration of the second dose, the PCA bolus was reduced by 0.5 mg every hour, until there was no nausea. Pruritus was treated only if severe. The skin was examined to eliminate other causes of pruritus. Clemastinum 2 mg was administered. If this drug was not effective, the PCA bolus was reduced by 0.5 mg every hour, until pruritus was relieved. Dreams and hallucinations were defined as any sensation that was not caused by an external event and were categorized as pleasant or unpleasant. In the presence of unpleasant dreams or any hallucinations (even pleasant), the PCA bolus was reduced by 0.5 mg every hour, until these symptoms were alleviated. Unsatisfactory treatment was defined as the occurrence of one of the following situations: 1) inadequate analgesia: pain score >0 at rest and >2 during mobilization after 2.5 mg PCA boluses, repeated six times in 1 h; 2) side effect: (a) is not relieved despite reduction in PCA bolus, (b) is alleviated after reduction in PCA bolus, but analgesia is inadequate. If the above protocol to deal with pain and side effects was not successful, individual pain treatment was planned. Modifications in the PCA drug combination, in the lockout interval, addition of other analgesics or change from PCA to another form of pain therapy were the available options. The PCA was discontinued when patients required an average of <1 PCA bolus per hour during the last 12 h.
Data Collection Data concerning the patient were gender, age, weight, ASA class and type of surgery. Data concerning the intraoperative phase were type of anesthesia (general, regional or combined) amount of morphine and fentanyl administered and duration of operation. In the postoperative phase, during the time in which PCA was used, the following data were assessed for each patient every 2 h during the first 6 h and every 4 h thereafter: pain intensity using the verbal rating score, sedation score, systolic blood pressure, heart rate, presence of dreams and hallucinations, respiratory rate, presence of nausea, vomiting, and pruritus. In addition, total consumption of PCA drugs and duration of the PCA use were recorded. Direct medical costs were calculated from the total amount of additional ketorolac or metamizole, type and dose of drugs to treat the side effects and acute pain service teams additional time to manage inadequate analgesia and adverse effects. To assess the number of patients with chronic postoperative pain, patients were mailed a form 3 and 6 mo after the operation. Patients were asked if they still had pain at the same location as before the operation and, if so, to rate the intensity on a visual analog scale. Furthermore, patients were asked whether their pain was less, equal or worse than the pain before surgery.
Statistical Analysis Backward stepwise regression was used to identify the predictors of unsatisfactory treatment, with unsatisfactory treatment as dependent variable and the following independent variables: drugs used, type of surgery, type of anesthesia, intraoperative administered fentanyl, ASA class, maximum bolus administrated, pain score, duration of PCA therapy, and consumption of PCA drugs.
All the other parameters, numerical and categorical data were compared by the Students t-test and the Since analyzing so many secondary outcome parameters may provide a statistically significant difference as the result of pure chance, we deliberately used descriptive statistics only and decided not to use Bonferroni correction of the Students t-test. RESULTS Of the 401 patients enrolled, 49 were not included in the analyses for the following reasons: intraoperative protocol violation (23 patients), postoperative protocol violation,14 postoperative use of indometacin for ectopic ossification prophylaxis,11 surgical revision.1 The study was therefore completed in 352 patients. The two groups were comparable (Table 2).
There were no differences between the groups with respect to the primary end-point (unsatisfactory treatment, Table 3). The incidence of respiratory depression was more frequent in Group MK, i.e., 10.8% vs 5.1% in Group M (P = 0.075) as well as the need to administer additional analgesic and ondansetron (Table 3). No differences were found in other secondary end points: adverse effects, pain scores, consumption of administered drugs (Fig. 1), duration of PCA therapy, additional visits from the acute pain team (Table 3) or incidence and intensity of chronic pain (Table 4). Only 25.9% and 10.2% of all patients returned our chronic pain questionnaire 3 and 6 mo after the surgery, respectively.
Results of backward stepwise regression show that unsatisfactory treatment can be predicted from pain score at rest, duration of PCA therapy, and the consumption of PCA drugs. PCA regimen used, type of surgery, type or duration of anesthesia, ASA class, amount of drug administered per bolus, and intraoperative consumption of fentanyl were not significant predictors and were progressively removed from the model (Table 5).
DISCUSSION The available literature on a morphine-ketamine combination for postoperative IV PCA is conflicting (Table 6). Studies on a morphine-ketamine combination after major abdominal surgery investigated a small number of patients and no study has been performed in a large number of patients who underwent orthopedic surgery.18 In this double-blind, randomized trial with a large number of patients, we rejected the hypothesis that small-dose ketamine is a useful adjunct to morphine PCA after major elective orthopedic surgery.
The combination of morphine with ketamine used in this study was based on the possible optimal combination indicated in our previous study in which patients undergoing major hip and spine surgery were investigated.12 We therefore assumed that the combination found could be generalized for patients undergoing major orthopedic surgery. There was no significant difference between groups regarding primary or secondary outcome variables. Pain scores recorded were low (Table 3). Higher demand for additional analgesic in the Group MK was not statistically significant and might have been the result of pure chance. Edwards et al.19 found no beneficial effect of ketamine on postoperative lung function, even though the bronchodilator effect of ketamine is well known. Interestingly, in our study, respiratory depression was more frequent, although not statistically significant, in the Group MK than in Group M alone. In general, the incidence of side effects in our study was more frequent than the incidence reported in the literature (Table 3).10,11,18 It is possible that the incidence of side effects was under-estimated in previous studies. The average ketamine consumption in the present study was 1.86 mg/h, which is comparable with the results of previous studies.10 In the study conducted by Javery et al.7 the average ketamine consumption was 1.2 mg/h and the addition of ketamine produced a remarkable effect after elective microdiscectomy. In the study by Reeves et al.,8 the average ketamine consumption in the first 24 h after major abdominal surgery was 3.2 mg/h, yet they did not find any measurable beneficial effect. The same average ketamine consumption was observed by Murdoch et al.20 in a study on a small patient group that underwent total abdominal hysterectomy. This study also failed to show any benefit of adding ketamine to morphine PCA. In a study of 30 patients, Adrieanssens et al.6 showed that 10 mg/h of ketamine had a morphine-sparing effect with reduction of nausea after abdominal surgery. Besides Javery et al.7 there is no study using morphine and ketamine PCA for treatment of musculoskeletal pain. The smallest ketamine plasma concentration to counteract hyperalgesia while producing minimal side effects was shown to be 60 µg/mL.21 This concentration was achieved by giving an initial bolus dose of ketamine 0.5 mg/kg, followed by a continuous infusion of 2 µg · kg–1 · min–1.22,23 In comparison, the average ketamine consumption in our study was more than six times lower, which might explain the negative result. In addition, continuous infusion of small-dose ketamine during PCA with morphine may be better than a PCA approach alone, because of a stable NMDA receptor block. On the other hand, it would reduce patients mobility, increase costs and may be less safe.24 Whether a continuous ketamine infusion is superior to PCA delivery is yet to be demonstrated by a large, randomized, controlled trial. Because of the very low return rate of our questionnaire regarding chronic pain (only 10.2% of all patients returned a questionnaire 6 mo after the surgery), no conclusions can be made regarding the influence of ketamine on chronic pain, a more active manner of collecting long-term data is needed to assure quality data collection. Further studies are needed in subgroups of patients to investigate if the addition of ketamine to an opioid may be considered as adjunctive therapy instead of routine use. Patients with morphine-resistant pain,25 opioid tolerance,26 or addiction27 may be possible target groups. In conclusion, we failed to demonstrate any beneficial effect of routinely adding ketamine to morphine for PCA after major orthopedic surgery.
Footnotes Accepted for publication August 27, 2007. Presented at ASA Annual Meeting on October 24, 2005, in Atlanta, Georgia, and at Swiss Society of Anesthesiology Annual Meeting on November 4, 2005, in Interlaken, Switzerland. Reprints will not be available from the author. REFERENCES
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|